Medical Digest & Congress Report

Professor Josep Redon chaired an interesting session on Diabetes and Metabolic risk factors at ESH 2024. Video: https://medicaldigest.org/scientific-contents/interview:diabetes-and-metabolic-risk-factors

Professor Michael Böhm on evolving standard of care and SGLT2 inhibitors for patients with CKD and hypertension. Video: https://medicaldigest.org/scientific-contents/interview:nephroprotection-using-sglt2-inhibitors-patients-hypertension

Professor Roland Schmieder, Co-Chair of ESH 2024 on the ESH 2024 Congress and the updated Guidelines. Video: https://medicaldigest.org/scientific-contents/interview:esh-clinical-practice-guidelines

We asked Professor Antonio Almeida, the President of European Hematology Association about the benefits and perspectives in EHA as a European hematologist, about the highlights of this year EHA congress and about the new Guidelines. Video: https://medicaldigest.org/scientific-contents/standalonecontent:haematology-forefront-interview-eha-president

Professor Vasilios Kotsis on obesity induced hypertension and its state of the art treatment. Video: https://medicaldigest.org/scientific-contents/interview:obesity-induced-hypertension

Professor Roland Schmieder on the results of a prospective randomized sham-controlled study and explains the effects of renal denervation on blood pressure in patients with chronic kidney disease and uncontrolled hypertension Video: https://medicaldigest.org/scientific-contents/interview:hypertension-and-beta-blocker-choice-influence-age-stress-and-co-morbidities

Professor Sverre Erik Kjeldsen at the recent annual meeting of the European Society of Hypertension, held a lecture on the role of beta-blockers in the management of hypertension. Video: h ttps://medicaldigest.org/scientific-contents/interview:hypertension-and-beta-blocker-choice-influence-age-stress-and-co-morbidities

Professor Konstantinos Tsioufis shares his thoughts on the novelties of kidney protection in hypertension. Video: https://medicaldigest.org/scientific-contents/interview:overcoming-resistance-renal-denervation-solution

Professor Francesca Mallamaci co-chaired a session at the current Annual Congress of the European Society of Hypertension on cardiovascular protective effects of SGLT-2 inhibitors. The new drug class revolutionized the treatment of type-2 diabetes. What did we learn in the clinical trials about these drugs regarding nephroprotection, CV protection in the diabetic population? Video:

Professor Krzysztof Narkiewicz on why is it so difficult to reach the expected BP target in real-life patients. Video: https://medicaldigest.org/scientific-contents/interview:why-it-so-difficult-reach-expected-bp-target-real-life-patients

Professor Bryan Williams chaired an interesting symposium at ESH 2024. The joint ESH/ESC guideline on the diagnosis and treatment of hypertension and explained his thoughts on how to improve adherence in hypertension management. Video: https://medicaldigest.org/scientific-contents/interview:time-act-improve-adherence-hypertension-management-bridging-gap-between-knowledge-and-action

Professor Claudio Borghi chaired a symposium at ESH 2024 on two very important patient groups, diabetic patients and coronary patients, on antihypertensive treatment. Video: https://medicaldigest.org/scientific-contents/interview:real-life-hypertensive-patients-towards-holistic-approach-clinical-practice

Professor Sofie Brouwers explained at ESH 2024 that antihypertensive treatment for chronic coronary artery disease should be based on an ACE inhibitor and the evidence supporting this. Video: https://medicaldigest.org/scientific-contents/interview:hypertension-and-cad-need-more-spcs-report-esh2024

Professor Michel Burnier shared his thoughts on why is adherence is a key factor in good hypertensive management at ESH 2024. Video: https://medicaldigest.org/scientific-contents/interview:challenges-hypertension-adherence-treatment

Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the growing number of HPV-associated head and neck cancers in our interview. The right combination of treatment modalities - less and less invasive surgical procedures, increasingly precise radiotherapy options and systemic therapies, especially immunother...

Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most important breakthrough in the treatment of head and neck cancer patients has been the recent development of immunotherapy, which is also helping patients with advanced stage cancer, and expects the importance of drug therapies to increase in the future. H...

Professor George D. Dangas chaired the Featured Clinical Research on Monday and shared his insights on the trials about acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements. - Fractional Flow Reserve-guided Complete Or Culprit-only PCI In Patients With ST-elevation Myocardial Infarction - Intravascular Ultrasound-guided Versus Angiography-guided P...

Professor Andrew M. Kates shared his insights on Late-Breaking Clinical Trials II, presented during at ACC.24: - Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 Kardia-2 Study - Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safe...

Professor Athena Poppas shared his insights on the Late Breaking Clinical Trial sessions: - Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock: Results Of The Danger-shock Trial - A Selective Aldose Reductase Inhibitor (at-001) For Th...

Professor Mikhail Kosiborod shared his insights onthe STEP-HFpEF and STEP-HFpEF DM randomised trials. Discussed studies: -  Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials -  Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes Video: https://m...

ACC Immediate-Past President Edward T. A. Fry chaired the Late Breaking Clinical Trial V. and shared his insights on the trials: - Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) - Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Ra...

Professor Kathryn L. Berlacher shared his insights on Late-Breaking Clinical Trials IV, presented during at ACC.24: - Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycli...

Professor Douglas E. Drachman shared his insights on the Late Breaking Clinical Trial sessions about interventional cardiology trials which he co-moderated. - Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Card...

Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of patients treated...

David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels at one month after their last chemotherapy dose compared with those who did not take it, according to results from the PROACT study presented duri...